@article{24053,
  keywords = {Anti-Bacterial Agents, Humans, leprosy, Quinolones, Treatment Outcome, Tuberculosis},
  author = {Rubinstein E and Keynan Y},
  title = {Quinolones for mycobacterial infections.},
  abstract = {<p>The fluoroquinolones (FQs) are important agents for the treatment of mycobacterial infections. In leprosy, the use of FQs has enabled a dramatic shortening of formerly long and complicated therapy. Both animal and human studies support the inclusion of certain FQs as a cornerstone of leprosy therapy. In tuberculosis (TB), particularly in multidrug-resistant (MDR) infections, the place of the major antimycobacterial FQs is less clear as there is widespread resistance to these agents in areas of the world in which MDR-TB and extensively drug-resistant (XDR)-TB are prevalent, particularly in Southeast Asia. The place of the newly developed FQ-related diarylquinoline compound known as bedaquiline in the treatment of drug-resistant TB is unclear; however, human studies suggest that it might be effective for this indication. </p>},
  year = {2013},
  journal = {International journal of antimicrobial agents},
  volume = {42},
  pages = {1-4},
  month = {2013 Jul},
  issn = {1872-7913},
  doi = {10.1016/j.ijantimicag.2013.03.005},
  language = {eng},
}